CHAPTER 2

LITERATURE REVIEW

Quinine

Quinine, the chief alkaloid derived from the bark of cinchona tree, has been used in malaria suppression and treatment for more than 350 years. The principal areas producing cinchona are central Africa, India and Indonesia. Linneus gave the term cinchona in 1742. Jesuits probably brought the bark to Europe in 1631 or 1632 and again in 1645. In 1820, the structure of quinine was identified by Pelletier and Carventon (Krishna and White, 1996; Tracy and Webster, 1991) and complete synthesis of quinine was achieved in 1945 by Robert B. Woodward (Meesuk, 1978).

Quinine is recommended for the treatment of chloroquine-resistant \textit{P. falciparum} malaria and is an important drug of choice for treatment of complicated and/or cerebral malaria (Tracy and Webster, 1996) Besides treatment of malaria, quinine is also prescribed for nocturnal leg cramps in general practice (White, 1996; Tracy and Webster, 1996).

Chemical and Physical Properties

- Chemical structure: \( \text{C}_{20}\text{H}_{24}\text{N}_{2}\text{O}_{2} \)
- Synonyms: \( 6' \)-methoxycinchonan-9-ol
- Molecular weight: 324.4
pKₐ:

Quinuclidinyl group : 4.1
Quinolone group : 8.5

Solubility:

in ethanol : 1 in 1 (w/v)
in water : very low

(Dollery, 1999)

Quinine contains a quinoline group attached through a secondary alcohol linkage to a quinuclidine ring. A methoxy side chain is attached to the quinoline ring and a vinyl to the quinuclidine (Figure 1) (Tracy and Webster, 1996).

Karle et al. (1992) described that the conformation around atoms C-8 and C-9 of the cinchona alkaloids, particularly the direction of the aliphatic N-H and (9) O-H bonds relative to each other, are crucial to antimalarial activity.

![Chemical Structure of Quinine](image-url)

*Figure 1 Chemical Structure of Quinine*
1. Pharmacodynamic Properties

1.1 Mechanism of Action

The mode of action of quinine is still unclear. However, quinine is known to depress many enzyme systems. Quinine is highly concentrated and accumulates in the acid food vacuoles of malarial parasites. It inhibits the parasite enzyme hemepolymerase. This enzyme allows the incorporation of heme, which is toxic to the parasite, into insoluble (and apparently inert) crystalline material called hemozoin (Dollery 1999). Another possible of its mechanism is to form a hydrogen bond complex with double stranded DNA that inhibits strand separation, transcription and protein synthesis (Tracy and Webster, 1996 ; Goldsmith, 1992 ; Painisko et al., 1990).

1.2 Antimalarial Action

Quinine is a rapidly acting and highly effective blood schizontocide against four malarial parasites. The drug is gametocidal for *P. vivax*, *P. ovale* and *P. malariae* but not effective against for *P. falciparum* gametocytes. Quinine has no effect on sporozoites or the liver stages of the parasite (Goldsmith, 1992).

1.3 Pharmacologic Effects

1.3.1 Central Nervous System

Therapeutic doses of quinine have few effects on the central nervous system (CNS) other than to cause analgesia and antipyresis. The discovery that cinchona lowered the fever of malarial patients quickly led to its use in all forms of febrile illnesses. However, quinine is not a potent or particular effective antipyretic.
1.3.2 Cardiovascular System

The action of quinine on cardiovascular system includes Na⁺ current blockade and multiple cardiac K⁺ currents blockade. As a consequence of its K⁺ channel blocking actions, quinine prolongs action potentials in most cardiac cells. This effect is most prominent at slow rates. Quinine also produces α-adrenergic receptor blockade and vagal inhibition. Quinine, given intravenously as a bolus dose, can sometimes cause alarming and even fatal hypotension. However, in therapeutic doses it has little effect on the normal heart or blood pressure in humans (Webster, 1991).

1.3.3 Skeletal Muscle

It increases the tension response to a single maximum stimulus delivered to the muscle directly or through the nerve, and increases the refractory period of muscle so that the response to tonic stimulation is diminished. The excitability of the motor endplate region decreases as a result in responses to repetitive nerve stimulation and to acetylcholine was reduced. Thus, quinine can antagonize the actions of physostigmine on skeletal muscle as effectively as does curare. Quinine may cause symptomatic relief of myotonia congenita. This disease is the pharmacological antithesis of myasthenia gravis. Thus, quinine may produce alarming respiratory distress and dysphagia in patients with myasthenia gravis.

Quinine has a slight oxytocic action on the gravis uterus, especially in the third trimester (Goldsmith, 1992; Looareesuwan, 1995).
2. Oral Treatment of Falciparum Malaria Resistant to Chloroquine

Quinine is currently recommended for the treatment of chloroquine-resistant *P. falciparum* malaria and the drug of choice for the treatment of complicated and/or cerebral malaria (WHO, 1990). In adults with uncomplicated falciparum malaria are quinine sulphate 600 mg every 8 hours combined with tetracycline 250 mg every 6 hours for 7 days (Karbwang and Cross, 1997; Looareesuwan, 1995).

3. Other Use

Quinine is widely used as a treatment for nocturnal leg cramps. The dose of quinine is 200 to 300 mg before retiring (White, 1996; Tracy and Webster, 1996).

4. Therapeutic Range

After standard therapeutic dose, peak plasma levels of quinine may reach 15-20 mg/l in severely ill Thai patients without major toxicity (Tracy and Webster, 1996). The blood concentration of quinine required for optimum parasiticidal effect are not certainly known, but most investigators have aimed to achieve a total plasma level over 8-15 mg/l more than 7 days in severe drug-resistant malaria and should not result in toxicity in severe falciparum malaria (White, 1988).
5. Adverse Effects

5.1 Gastrointestinal Effect

Most quinine salts taken orally have an extremely bitter taste and irritant to the gastric mucosa and often cause nausea, vomiting or epigastric pain (Painsko and Keystone, 1990).

5.2 Cinchonism

Cinchonism is the common symptom, which frequently occurs when plasma quinine levels exceed 5 mg/l. These symptoms are tinnitus, vertigo, transient loss of hearing, nausea, vomiting, abdominal pain, dysphoria, headache and blurred vision (Painsko and Keystone, 1990) and it usually develops when plasma levels of quinine exceed 7-10 mg/l; in some patients, however, symptoms may occur at lower plasma level (Goldsmith, 1992).

5.3 Hematologic Effects

Quinine induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome, which were directed against the platelet glycoprotein complexes GPI/IX and GPIIb/IIIa, endothelial cells and leukocytes (Glynne et al., 1999). Another report of hemolysis directly attributable to quinine occurs in 0.05% of people treated for acute malaria; it may also occur in glucose-6-phosphate dehydrogenase-deficient patients. However, leukopenia, agranulocytosis, thrombocytopenic purpura, Henoch-Schonlein purpura and hypoprothrombinemia are rare.

Quinine has a peripheral vasodilator action and has been associated with marked postural hypotension in patients being treated for acute
falciparum malaria. This symptom occurs when infusions are rapid (Supanaranond et al., 1993 and Kofi-Ekue et al., 1988). It postulated that this effect is mediated by the inhibition of the action of aldosterone and angiotensin (Hadjokas and Goodfriend, 1991).

5.4 Hypoglycemia

Hypoglycemia occurs commonly during intravenous therapeutic doses of quinine (White et al., 1983b). Quinine stimulates insulin release from pancreatic beta cell, both in healthy subjects and patients (White et al., 1983b; Dyer et al., 1994) and may cause recurrent hyperinsulinaemic hypoglycemia. This important complication is marked with pregnancy and severe disease.

6. Severe Toxicity

In the recommended doses, serious adverse effects are infrequent. While in patients on chronic therapy, toxic effects of quinine generally occur with levels of more than 10 mg/l (Powell and McNamara, 1972). Boland et al. (1985) suggested that patients with ocular toxic effects are likely to have plasma quinine level 15 mg/l after ingestion and more than 10 mg/l after 10 hours. In cases study of Dyson et al (1985) since 1953-1983 of the 46 patients with toxicity was found that visual loss occurred in concentration above 10 mg/l, 8 patients developed visual symptom, blindness in six, appreciable constriction of the peripheral fields in one and abnormal color vision in one. Blindness developed 4.5-14 hours after ingestion. Of 71 further patients reported during 1963-1983, cardiovascular toxicity was unusually mild and was found in 24 patients. Two of the three deaths reported, however, were due
to arrhythmia and ventricular tachycardia occurred in one patient, who has the highest plasma concentration (23.5 mg/l). The arrhythmia ended spontaneously eight hours after ingestion. Twenty-four hours after ingestion the patient developed gross pulmonary edema. Electrocardiograms from 17 other patients all showed some abnormality. Arrhythmia were associated with plasma concentration above 16 mg/l. Quinine intoxication following doses of 4 to 12 g is characterized by seizures and coma. Early symptoms are mild visual and hearing complaints. A principal sign is the sudden onset of bilateral pupil dilatation. Lethal doses may be around 8 g (Phillips-Howard and Knile, 1995).

7. Pharmacokinetics Properties

7.1 In Normal Volunteers

7.1.1 Absorption

Quinine was well absorbed after oral administration in both healthy subjects and patients with uncomplicated malaria, the bioavailability is approximately 76-90 % (Hall et al., 1973; White, 1985; Paintaud et al., 1993). There is no difference when oral drug is given as capsules or tablets (Hall et al., 1973). Taggast et al. (1988) considered the quinine tablet almost completely absorbed, since less than 5% of the drug was recovered in the faces. The absorption occurs mainly from the upper small intestine (Tracy and Webster, 1996). In adult healthy subjects, the time to peak plasma drug concentration ($T_{\text{max}}$) was 1-4 hours (Karbwang et al., 1993; Paintaud et al., 1993; Wanwimolruck et al., 1991; Salako and Suwanmi, 1992). The peak
plasma concentration ($C_{\text{max}}$) for the therapeutic dose of quinine sulphate, 600 mg administered orally was 4.1-5.6 mg/l (Wanwimolruk et al., 1991; Jamaludin et al., 1988) and the rate of absorption in young and elderly subjects were similar (Wanwimolruk et al., 1991).

### 7.1.2 Distribution

The volume of distribution of quinine in normal subjects was 1.8 l/kg (White et al., 1983a; Dyer et al., 1994). Karbwang et al. (1993) showed that pharmacokinetic properties of intravenous quinine were adequately described by a two-compartment open model with a mean volume of central compartment ($V_c$) 0.3 l/kg (range 0.2 - 0.9) and a total mean apparent volume of distribution was 3.2 l/kg (range 1.8 - 4.6), which is similar to the study of Davis et al. (1988) and Guentent et al. (1979). Whereas, oral and intramuscular quinine could be described by a one-compartment open model (Supanaranond et al., 1991; Dyer et al., 1994).

The ratio of cerebrospinal fluid to free plasma quinine was $0.55 \pm 0.33$, which suggests that quinine does not freely cross the blood brain barrier (Silamut et al., 1985).

### 7.1.3 Plasma Protien Binding of Quinine

In healthy subjects, plasma protein binding expressed as the percentage quinine was 69-92% (Wanwimolruk and Denton, 1992). Quinine is mainly bound to $\alpha_1$-acid glycoprotein with a high affinity, low capacity binding profile in plasma but also to a less extend with albumin (Van Hensbroek et al., 1996; Mihaly et al., 1987).
7.1.4 Elimination

Quinine undergoes extensive hepatic biotransformation, less than 20% of an administered dose were excreted unchanged (Tracy and Webster, 1996). Wanwimolruk et al. (1995) showed that the metabolites of quinine were at least seven possible metabolites detected in human urine. Three of these were identified as 2'-oxoquininone, quinine glucuronide and 3-hydroxyquinine. The major metabolic pathway of quinine has been shown to be 3-hydroxylation mediated mainly by human CYP3A4 (Mirghani et al., 1999; Zhao and Ishizaki, 1997; Zhang et al., 1997).

The clearance of quinine varies between 0.072 and 0.24 l/hr/kg in healthy individuals and was reduced to approximately 0.062 l/hr/kg in elderly subjects (Krishna and White, 1996). White (1985) reported that the total systemic clearance of quinine is approximately 0.15 l/hr/kg in adult subjects. The mean terminal elimination half-life in healthy subjects was 10-13 hours (Wanwimolruk et al., 1991; Salako and Sowanmi, 1992; Karbwang et al., 1993; Paintaud et al., 1993).

7.2 In Uncomplicated Malaria

7.2.1. Absorption

The rate of quinine absorption in acute phase compared to convalescence phase was not significantly different. When given orally, it was well absorbed and oral bioavailability of quinine sulphate probably exceeds 80% (Supanaranond et al., 1991; Sabchareon et al., 1982). The concentration at steady state was achieved in day 2 after receiving standard dose of quinine.
7.2.2 Distribution

The volume of distribution in uncomplicated falciparum malaria was smaller than convalescence (Sabchareon et al., 1982). The contraction in volume of distribution may be related to several factors such as dehydration, obstruction of the capillary bed by parasited red cells and alterations in tissue binding (White et al., 1982).

7.2.3 Elimination

White et al. (1982) studied in 13 uncomplicated falciparum malarial patients and found that the quinine CL is $1.35 \pm 0.6$ ml/min/kg, and White (1985), the total clearance of quinine is approximately 0.084 l/hr/kg (1.4 ml/min/kg) in uncomplicated malaria and 0.054 l/hr/kg (0.9 ml/min/kg) in cerebral malaria. Thus the quinine clearance reduces relative to severity of disease because the liver function in malarial infection is decrease.

7.3 In Severe Malaria

In severe malaria, the systemic clearance of quinine is reduced, presumably on the basis of reduced hepatic blood flow and a subsequent decrease in the metabolism of quinine (Tracy and Webster, 1996; Looareesuwan, 1995; White et al., 1982).

7.3.1 Absorption

In cerebral malaria, patients who received a loading dose (20 mg/kg quinine hydrochloride, infused over 4 hours) has plasma concentrations exceeding 10 mg/l and time to reach a peak is $48 \pm 22$ hours after treatment began (White et al., 1983a).
7.3.2 Plasma Protein Binding

The mean percentage of unbound quinine was significantly lower in patients with cerebral malaria (7.2%) than uncomplicated malaria and healthy persons (Silamut et al., 1985). Plasma α₁-acid glycoprotein concentrations were consistently raised in acute malaria and cerebral malaria may be prevent quinine toxicity in the presence of high quinine plasma concentration (Wanwimolruk and Denton, 1992; Mansor et al., 1991; Silamut et al., 1991).

7.3.3 Distribution

Quinine mean total apparent volumes of distribution (Vd) in 25 cerebral malarial patients were 1.18 l/kg; this was significantly lower than uncomplicated malaria (1.67 l/kg) (White et al., 1982).

7.3.4. Elimination

In cerebral malaria, a reduction in systemic clearance 0.054 l/kg and prolonged half-life (18 hr) resulted from impaired hepatic metabolism. Malarial infection reduced the concentration of cytochrome P450 in liver microsomes (Dollery, 1999; White et al., 1982).

7.4 In Children with Malaria

There are significant pharmacokinetic differences between adults and children. In children, volume of distributions was smaller and elimination half-life was shorter than adult (Sabchareon et al., 1982).

7.4.1 Absorption

Quinine was rapidly and completely absorbed either by intramuscular or nasogastric administration (Van Hensbroek et al., 1996; Shan et al., 1985).
Sabchareon et al. (1982) found that the highest mean serum quinine concentration (22.5 nM/ml) in acute malaria is higher than in convalescent children (10.17 nM/ml) after oral administration (10 mg/kg). The time to reach peak plasma concentration after oral administration is 2 to 4 hours, whereas after intravascular infusion there were no significant differences.

The peak plasma quinine concentration after rapid intravenous dosing (4.0 mg of the salt /kg body weight) in 4 min was 12.3 mg/l, which was 43% higher than in adults given the same regimen (Winstanley et al., 1993).

7.4.2 Distribution

The mean volume of distribution in children with falciparum malaria after intravenous infusion, intramuscular and nasogastric administration of quinine dihydrochloride was 1.51, 1.29 and 1.33 l/kg, respectively. There was no significant difference in the volume of distribution of quinine among children with cerebral and uncomplicated malaria (Shann et al., 1985). Van Henbroek et al. (1996) studied in children under 2 years and found that the mean volume of distribution after intravenous and intramuscular administration was 1.04 l/kg.

7.4.3 Elimination

The elimination half-life in falciparum malaria by intravenous infusion at the dose of 10 mg/kg range from 9 to 12 hours which were longer than in the convalescence (3.2 to 7.55 hours) and it neither depends on the route nor the duration of infusion of the drug although total clearance values are similar to adult (Sabchareon et al., 1982).
7.5 In Pregnancy

Pregnant women with falciparum malaria in the third trimester showed significant pharmacokinetic differences when compared with other adults in the acute phase of malarial infection. The values of volume of distribution were smaller (0.96 ± 0.27 l/kg), elimination half-lives were shorter (11.3 ± 4.3 hr) and total clearance was reduced (1.22 ± 0.77 ml/min/kg). 8 women delivered of live infant while taking quinine had placental cord plasma quinine concentrations from 1 to 4.6 mg/l, which correlated significantly with maternal plasma quinine concentrations. Heart blood from fetus aborted at term has a plasma quinine concentrations of 2.8 mg/l. Breast milk quinine concentrations and milk to plasma ratio were 0.5 to 3.6 mg/l and 0.11-0.53, respectively in 25 women who were breast-feeding and had taken oral quinine sulphate for 1-10 day (Phillips et al., 1986).

7.6 In Renal Failure

The urinary quinine clearance comprises only 20% of total clearance in healthy subjects. Donadio et al. (1968) reported that the plasma concentration of 6 patients with falciparum malaria in acute phase of renal failure was higher and they concluded that the dose of quinine in renal failure should be reduced by one-half to two-thirds to avoid potential toxicity.
8. Drug Interaction

8.1 Antimalarial and Non-antimalarial Drugs (in vitro)

Of the twenty-three tested compounds incubated with liver microsomes and quinine, 13 exhibited an inhibitory effect on quinine 3-hydroxylation. All of these drugs inhibited the liver microsomal metabolism of quinine in a concentration dependent manner, but the magnitude of the inhibition differed among them. The inhibitory rank order were as follows: ketoconazole > doxycycline > omeprazole > primaquine > tetracycline = troleandomycin > nifedipine > erythromycin > verapamil > cimetidine > diltiazem > oleandomycin > hydralazine. The antimalarial drugs, doxycycline, primaquine and tetracycline, inhibited quinine 3-hydroxylation with mean IC$_{50}$ values of 17, 20 and 29 µM, respectively. Non-antimalarial drugs, calcium-antagonists (verapamil, nifedipine and diltiazem), macrolide antibiotics (troleandomycin, erythromycin, and oleandomycin), ketoconazole, omeprazole and cimetidine are inhibitors/substrates of CYP3A4. Ketoconazole was a potent inhibitor of quinine metabolism with mean IC$_{50}$ values of 0.026 µM. A significant interaction may occur when these drugs are administered concomitantly with quinine in vivo (Zhao and Ishizaki, 1997).

8.3 Etoposide (in vitro)

Etoposide, an anticancer agent with a broad range of antitumor activity, is claimed to be metabolized largely via CYP3A4 by 3'-demethylation in human liver microsomes and its metabolite has the same antitumor activity. Quinine and etoposide were metabolized mainly by the same human CYP isoform. Etoposide showed the inhibitory of microsomal metabolism of quinine 3-
hydroxylation in a concentration–dependent manner with a mean IC$_{50}$ values of 65 μM and the mean maximum inhibition produced by etoposide (100 μM) on the 3-hydroxylation of quinine was about 60% compared with the control. Etoposide 3′-demethylation was also inhibited by quinine in a concentration-related manner with a mean IC$_{50}$ values of 90 μM. The mean maximum inhibition produced by quinine (100 μM) on 3′-demethylation of etoposide was about 52% compared with control. An excellent correlation ($r = 0.947, p < 0.01$) between quinine 3-hydroxylase and etoposide 3′-demethylase activities in 6 different human liver microsome was observed. Two inhibitors of CYP3A4, ketoconazole (1 μM) and troleandomycin (100 μM), inhibited quinine 3-hydroxylation by about 90% and 80%, and etoposide 3′-demethylation by about 75% and 65%, respectively. Conclude that quinine and etoposide mutually inhibit the metabolism of each other (Zhao et al., 1997)

8.4 Cimetidine

After cimetidine (1 g/day) pretreatment for 7 days there was a significant reduction in the apparent oral clearance of quinine from $0.182 \pm 0.063$ to $0.133 \pm 0.055$ l/hr/kg. This was reflected in a 49% (range 17 to 90%) increased in the mean elimination half-life from $7.6 \pm 1.3$ to $11.3 \pm 3.7$ hours. A reduction in clearance of quinine during the treatment of cimetidine found in this study would be due to inhibition of the hepatic mixed-function oxidase system by cimetidine (Wanwimonruck et al., 1986).
8.5 Cigarette Smoking

The mean $\text{AUC}_{0-\infty}$ in smokers was significantly less than non-smokers. Cigarette smoking increased quinine clearance by 77%. The mean unbound clearance ($\text{CL}_{u/f}$) of quinine were significantly greater, mean half-life was significantly shorter than non-smokers. The mean 48 hours recovery (% of dose) of unchanged quinine in the urine was lower in the smokers.

Quinine is extensively metabolized by hepatic oxidative biotransformation and is considered a low clearance drug with a narrow therapeutic window and it is well known that cigarette smoking predominately induced the P450 enzyme family. Cigarette smoking enhanced hepatic metabolism of quinine, total quinine clearance was increased but renal clearance not altered (Wanwimolruk et al., 1993).

Table 1 has shown the pharmacokinetic parameters in some published studies in healthy volunteers after oral administration of quinine.
Table 1  Some published pharmacokinetic data of quinine given orally in healthy male subjects

<table>
<thead>
<tr>
<th>No. of subject</th>
<th>Mean age ± S.D. (mg)</th>
<th>Dose (µg/ml)</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (µg/ml)</th>
<th>T&lt;sub&gt;max&lt;/sub&gt; (hr)</th>
<th>t&lt;sub&gt;1/2&lt;/sub&gt; (hr)</th>
<th>Vd (l/kg)</th>
<th>CL/f (l/hr/kg)</th>
<th>AUC (mg/l/hr)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>63.1 ± 6.5</td>
<td>600</td>
<td>3.7 ± 0.8</td>
<td>-</td>
<td>19.9 ± 6.3</td>
<td>1.7 ± 0.56</td>
<td>0.06 ± 0.02</td>
<td>-</td>
<td>Dyer, 1994</td>
</tr>
<tr>
<td>9</td>
<td>30.3 ± 3.4</td>
<td>600</td>
<td>4.6 ± 1.0</td>
<td>2.5</td>
<td>11.1 ± 3</td>
<td>-</td>
<td>0.14 ± 0.05</td>
<td>66 ± 20</td>
<td>Wanwimolruk, 1995</td>
</tr>
<tr>
<td>6</td>
<td>37-50</td>
<td>600</td>
<td>3.45</td>
<td>1.6</td>
<td>9.7</td>
<td>2.78</td>
<td>0.17</td>
<td>-</td>
<td>Auprayoon, 1995</td>
</tr>
<tr>
<td>7</td>
<td>21-29</td>
<td>600</td>
<td>2.7 ± 0.5</td>
<td>2.8 ± 1.4</td>
<td>11.4 ± 2.7</td>
<td>2.5 ± 1.4</td>
<td>0.17 ± 0.02</td>
<td>30 ± 3.5</td>
<td>Suwanmi and Salako, 1996</td>
</tr>
<tr>
<td>8</td>
<td>28.5 ± 3.1</td>
<td>600</td>
<td>5.68 ± 2.48</td>
<td>1.35 ± 0.53</td>
<td>10.07 ± 1.20</td>
<td>1.91 ± 0.6</td>
<td>0.13 ± 0.05</td>
<td>90.23 ± 43.39</td>
<td>Ridtitid et al., 1998</td>
</tr>
<tr>
<td>9</td>
<td>16-37</td>
<td>300</td>
<td>2.35 ± 0.52</td>
<td>1.76 ± 0.59</td>
<td>9 ± 2.13</td>
<td>1.97 ± 0.61</td>
<td>0.17 ± 0.09</td>
<td>36.06 ± 14</td>
<td>Present Study</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Azole Antimycotics

Azole antifungal agents are the synthetic compounds with one or more five-membered ring, where each ring contains either 2 (imidazoles) or 3 (triazoles) nitrogen atoms. The azoles antifugal are less toxic than amphotericin B and effective in many different fungi (Lyman and Walsh, 1992). Imidazoles and triazoles share the same antifungal spectrum and mechanism of action. The systemic triazoles are more slowly metabolized and have less effect on human sterol synthesis than do the imidazoles. Of the drugs now on the market in the United States, clotrimazole, miconazole, ketoconazole, econazole, butoconazole, oxiconazole, and sulconazole are imidazoles; terconazole, itraconazole, and fluconazole are triazoles (Bennett, 1996).

Mechanism of Action

The azole antifungal agents are inhibitors of the biosynthesis of ergosterol, a major component of the cell membrane of yeast and fungal cells. It replaces the precursor lanosterol, which is a substrate of the fungal cytochrome P450 enzyme, lanosterol 14-α-demethylase, which catalyses the conversion of lanosterol to ergosterol. Imidazoles and triazoles thus impair the biosynthesis of ergosterol for cytoplasmic membrane and lead to the accumulation of 14-α-methylsterol. On the molecular level, one of the nitrogen atoms of the azole ring is though to bind to the heam moiety of the fungal cytochrome P450 enzyme lanosterol 14-α-methylase, thereby interrupting the conversion of lanosterol to ergosterol. These methylsterols
may disrupt the close packing of acyl chains of phospholipids, altering the permeability of fungal cell walls, impairing the functions of certain membrane-bound enzyme systems and inhibiting growth (Lyman and Walsh, 1992; Bennett, 1996; Dollery, 1999).

**Ketoconazole**

Ketoconazole is a synthetic imidazole derivative (Figure 3), the first orally absorbable antifungal azole, was introduced in 1979 (Lyman and Walsh, 1992). It offered a number of significant advantages, including its broad spectrum of antifungal activity and wide tissue distribution. But strong inhibitory effect on cyclosporin oxidase and testosterone 6β-hydroxylase activity in human (Baldwin *et al.*, 1995).

**Chemical and Physical Properties**

Chemical structure: \( C_{28}H_{28}Cl_2N_4O_4 \)

Synonyms: *cis*-1-Acetyl-4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolam-4-yl]methoxy]phenyl]piperazine

Molecular weight: 531.4

pKa: 6.51, 2.94

Solubility:

- in alcohol: 1 in 54 (w/v)
- in water: almost insoluble

Octanol/water partition coefficient: 5400 (pH 11.8)

(Dollery, 1999)
1. Pharmacokinetics

1.1 Absorption

Ketoconazole is a lipophilic with poor water solubility except at low pH (pH < 3). Ketoconazole was well absorbed after oral administration although there is large inter- and intraindividual variation in peak serum concentration after the same dose and absorption increased in the presence of a meal. Antacid or H₂ antagonists reduced absorption of ketoconazole, thus should take these drug at least 2 hours before ketoconazole (Van Der Meer et al., 1980).

Peak serum concentrations of ketoconazole occur within 3 hours of administration and are proportional to dose (Daneshmend et al., 1981).
1.2 Distribution

The drug is rapidly and widely distributed throughout the body in animal and human. However, the volume of distribution was only 0.36 l/kg (Van Tyle, 1984). Ketoconazole is extensively bound in human whole blood (99%), with 84% to plasma proteins, largely albumin and 15% to erythrocytes (Heel et al., 1982). Penetration into saliva is high and detectable; penetration into CSF occurs only in the presence of inflamed meninges (Brass et al., 1982). And concentrations attainable are inadequate for treatment of fungal meningitis (Graybill et al., 1980). In dogs, the drug has been detected in breast milk at 22% of peak plasma values and it is therefore contraindicated in nursing mothers.

1.3 Elimination

Ketoconazole is extensively metabolized in the liver, the major route of elimination being as metabolites in bile. In three human volunteers given $^3$H-ketoconazole 2.5 mg/kg about 70% of the administered dose was excreted within 4 days (57% in faeces and 13% in urine). Of the faecal radioactivity 20-65% was due to unchanged drug and 2-4% of urinary radioactivity (Gascoigne et al., 1981). There may be enterohepatic circulation because the double peaks plasma concentrations, seen at higher doses of ketoconazole (Brass et al., 1982). It has been suggested that the elimination of ketoconazole was impaired in liver disease.

The major metabolic reactions in humans are oxidation of the imidazole ring followed by degradation of the oxidized imidazole, oxidative
degradation of piperazine ring and aromatic hydroxylation (Danesmend and Warnock, 1988). Ketoconazole itself appears to be oxidized by CYP3A.

The elimination half-life appeared to be dose dependent, increasing with increasing dose and after repeated dosing (Daneshmend et al., 1983). With an oral dose of 200 mg the range of mean ketoconazole half-life 1.51 to 4 hours. At higher dose (400 and 800 mg) the mean half-life were 3.7 hours (range from 1.3 to 11.6 hours) (Maksymink et al., 1982).

2. Therapeutic use

2.1 Systemic mycoses: paracoccidioidomycosis, coccidioidomycosis, candidosis and histoplasmosis.

2.2 Severe chronic mucocutanous candidosis

2.3 Disabling candidal chronic paronychia

2.4 Severe mycoses of the gastrointestinal tract not responsive or resistant to other therapy

2.5 Chronic vaginal candidosis not responsive to other therapy

2.6 Prophylaxis in immunosupressed patients

2.7 Culturally determined dermatophyte infections unresponsive to other therapy

2.8 Treatment of dermatophyte (ringworm) infections, cutaneous candidosis, pityriasis versicolor, seborrheric dermatitis and pityriasis capitis (dandruff) caused by *Pityrosporum* spp.
Mode of Use

The treatment of systemic mycosis and dermatophyte infections is normally 200 mg ketoconazole daily for 14 days, or longer if clinical response is poor. The dose may be increased to 400 mg daily if response to 200 mg daily is poor. However, it may be wise to measure plasma levels before increasing the dose (maximum 8 mg/kg daily) (Dillers, 1999).

3. Adverse Effect

The most frequent dose-limiting side effects of ketoconazole therapy are nausea and vomiting (Dismukes et al., 1983). They occur in approximately 10% of patients receiving 400 mg/day but increase to more than 50% in patients receiving more than 800 mg/day (Sugar et al., 1987). Pont et al. (1984) found that when given ketoconazole in conventional dose (400 mg/day), transiently blocks of testosterone synthesis and adrenal response to corticotrophin were noted. Higher therapeutic doses (800 to 1200 mg/day), even once daily, caused more prolonged blockade. Oligospermia and azospermia occurred after prolonged therapy. Impotence and decreased libido were found. Gynecomastia appeared in high dose more commonly than with lower dose. Depressed response to corticotrophin was pronounced. Urine cortisol excretion was depressed. The blockade appear related to the serum ketoconazole concentration. Trachtenberg (1984) observed in 13 patients with symptomatic stage D2 prostatic cancer administered 400 mg ketoconazole orally every 8 hours and found that by 24 hours of treatment serum testosterone decreased to the castrate level and the adrenal androgens,
androstenedione and dehydroepiandrosterone, also decreased significantly. After one week of treatment clinical response was evident in all patients. Pain was improved and serum prostatic acid phosphatase reached the normal range. The patients have been followed for 3 to 10 months without relapse. Approximately 10% of females report menstrual irregularities (Bennet, 1996) and 1 in 10,000 patients receiving ketoconazole associated with hepatotoxicity and 2 to 8% had some abnormal elevation of serum transaminase and usually reversible if treatment is stopped. The risk of hepatotoxicity increases with longer duration of treatment; courses of greater than 14 days should only be given after consideration of risks (Lewis et al., 1984).

4. Drugs Interaction

4.1 Oral Anticoagulants

A patient had been treated with warfarin for three years for a pulmonary embolism, and later received ketoconazole 200 mg twice daily for chronic vaginal thrush infection. After three weeks of treatment with ketoconazole she complained of subcutaneous bruising and reported to the clinic, whereas platelet count and liver function tests gave normal results. Treatment of ketoconazole was stopped, warfarin dosage reduced. Over the next three weeks her warfarin control was restabilised at previous level (Smith, 1984).

4.2 Chlordiazepoxide (Benzodiazepine)

Chlordiazepoxide is extensively oxidized in the liver with little urinary excretion of the parent drug. Ketoconazole impaired chlordiazepoxide clearance from plasma. After a single dose of ketoconazole, there was a 20%
decrease in clearance and 26% decrease in volume of distribution without
evidence of inhibition of drug metabolism. These changes apparently were not
related to ketoconazole dose. After repetitive dosing with ketoconazole,
chlor Diazepoxide clearance decreased by 38% and was associated with
reduced concentrations of its first oxidative metabolite, N-
Desmethylchlor Diazepoxide. It was concluded that ketoconazole inhibits at
least one subset of the hepatic mixed-function oxidase system, but not
generally (Brown et al., 1985).

4.3 Tirilazad

Tirilazad mesylate is a membrane lipid peroxidation inhibitor that shows
efficacy in reducing the damaging effects of lipid peroxidation on the cell
membrane triggered by brief periods of ischemia. Tirilazad is highly
metabolized after intravenous administration in healthy volunteers. It was
postulated that the limited bioavailability was due to extensive first-pass
metabolism in the liver. The major pathways of tirilazad metabolism in man
are mediated by the CYP3A. Pretreatment with ketoconazole for 7 days
results in increased mean tirilazad mesylate AUC by 67% and 309% for
intravenous and oral administration, respectively. Mean AUC for active
reduced metabolite of tirilazad (U-89678) were increased 472% and 720% by
ketoconazole administration with iv and oral tirilazad, respectively, whereas
increases of more than 10-fold in mean U-87999 (another active metabolites)
AUC. Ketoconazole increased the bioavailability 20.9% by decreasing the
first-pass liver and gut wall metabolism of tirilazad mesylate in similar
degrees. These results indicate that ketoconazole inhibits the metabolism of
three compounds (tirilazad, U-89678 and U-87999), which suggests that all of
the compounds are substrates for CYP3A (Fleishaker et al., 1996).

4.4 Nisoldipine

Nisoldipine is a calcium antagonist of the 1,4-dihydropyridine class. It
reduces vascular resistance and blood pressure by inhibiting calcium uptake of
myocardial and smooth muscle cells. Nisoldipine is extensively metabolized
by the cytochrome P450 system, with isoenzyme CYP3A4 catalyzing the
dehydrogenation of the dihydropyridine ring. Pretreatment with and
concomitant administration of ketoconazole resulted in a 24-fold and 11-fold
increase in mean AUC and $C_{\text{max}}$ of nisoldipine, respectively compare with
nisoldipine alone. The interaction is likely to be caused by inhibition of first-
pass metabolism, although an effect on systemic clearance cannot be ruled
out, because the terminal elimination phase was not assessable after treatment
with nisoldipine alone. The parallel increases in plasma concentration of the
metabolite 2-hydroxyisobutyl (M9) and parent drug indicate that side-chain
hydroxylation of nisoldipine in contrast to the oxidation of the
dihydropyridine ring is not mediated by CYP3A4 (Heinig et al., 1999).

4.5 Triazolam

Triazolam is a short-acting hypnotic having an average $t_{1/2}$ of 2 to 4 hours.
After oral administration, triazolam is metabolized during its absorption (first-
pass) and elimination phase by CYP3A4. Triazolam commonly causes
amnesia. Nine healthy volunteers received 400 mg ketoconazole, 200 mg
itraconazole, or matched placebo orally once a day for 4 days. On day 4, each
ingested a single 0.25 mg dose of triazolam. Ketoconazole and itraconazole
increased AUC of triazolam by 22-fold and 27 fold, $C_{max}$ by 3-fold, and $t_{1/2}$ by 6-fold and 7-fold, respectively. All pharmacodynamic effects revealed a significant difference between the antimycotics and placebo phases. Ketoconazole and itraconazole seriously affects the pharmacokinetics of triazolam and increase the intensity and duration of its effects by inhibition of CYP3A4 during the absorption and elimination phases of triazolam (Varhe, 1994).

4.6 Midazolam

Midazolam is a benzodiazepine that is used clinically for conscious sedation. It is specifically metabolized by CYP3A to one predominant metabolite ($1'$-hydroxymidazolam); it has a short half-life. After ketconazole therapy, AUC of midazolam increased 5-fold after intravenous midazolam administration and 16-fold after oral midazolam administration. Intrinsic clearance decreased by 84%. Total bioavailability increased from 25% to 80%. The intestinal component of midazolam bioavailability increased to a greater extent than hepatic component. In the control phase, female subjects had greater midazolam clearance values than the male subjects. Ketoconazole caused marked inhibition of CYP3A activity that was greater in the intestine than liver for midazolam biotransformation (Tsunoda et al., 1999). Olkkola et al. (1994) indicated that ketoconazole and itraconazole also increased the AUC by 10 to 15-fold and mean peak concentration 3- to 4-fold compared with placebo phase. In psychomotor tests, the interaction was statistically significant until at least 6 hours after drug administration. Inhibition of the
CYP3A by ketoconazole and itraconazole may explain the observed pharmacokinetic interaction (Olkkola, Backman and Neuvonen, 1994).

4.7 Quinidine

The oxidation of quinidine to 3-hydroxyquinidine is a specific marker reaction for CYP3A4 activity in vitro. Concomitant administration of diclofenac (a CYP2C9 substrate) reduced the partial clearance of quinidine by N-oxidation by 27%, while no effect was found for other pharmacokinetic parameters of quinidine. Concomitant administration of disulfiram (an inhibitor of CYP2E1) did not alter any of the pharmacokinetic parameters of quinidine. Concomitant administration of itraconazole reduced quinidine total clearance, partial clearance by 3-hydroxylation and partial clearance by N-oxidation by 61, 84 and 73%, respectively. The renal clearance was reduced by 60% and termination half-life increased by 35%. Concomitant administration of grapefruit juice reduced the total clearance of quinidine and its partial clearance by 3-hydroxylation and N-oxidation by 15, 19 and 27%, respectively. The elimination half-life of quinidine was increased by 19%. Concomitant administration of erythromycin reduced the total clearance of quinidine and its partial clearance by 3-hydroxylation and N-oxidation by 34, 50 and 33%, respectively. $C_{\text{max}}$ was increased by 39%. The caffeine metabolic index was reduced by 25% (Damkier, Hansen and Brosen, 1999).

4.8 Quinine

Mirghani et al. (1999) showed the effect of ketoconazole on quinine pharmacokinetics, it (which inhibits CYP3A4) significantly decreased the mean apparent oral clearance of quinine by 31%, whereas coadministration
with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect on the mean apparent oral clearance of quinine. Coadministration of ketoconazole also decreased the mean AUC of 3-hydroxyquinine, whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly.

Cytochrome P450 3A4 is important for the 3-hydroxylation of quinine in vivo. On the other hand, CYP1A2 had no significant effect on this metabolic pathway.

4.9 Reboxetine

Reboxetine is a specific norepinephrine reuptake inhibitor that is licensed in several European countries for treatment of depression. It is metabolized by CYP3A4. Eleven healthy volunteers received 4 mg reboxetine orally on the 2nd day of a 5 days regimen of 200 mg ketoconazole once daily in a crossover design. Ketoconazole increased R, R(-)-reboxetine and S, S (+)-reboxetine (more active reboxetine enantiomers) mean AUC by 58% and 43%, respectively (P < 0.02). Oral clearance of both enantiomers were consequently decreased 34% and 24%, respectively by ketoconazole (P < 0.05). Mean terminal half-life after administration of ketoconazole (21.5 and 18.9 hours) were significantly longer than after reboxetine alone (14.8 and 14.4 hours; P < 0.005). The AUC ratio for R, R (-)-reboxetine to S, S (+)-reboxetine was reduced by ketoconazole administration (12.76 after ketoconazole versus 2.39; P < 0.003).

Ketoconazole decreased clearance of both reboxetine enantiomers. Although the adverse effect profile for reboxetine was not altered by
ketoconazole, the results of this study suggest that caution should be used and that a reduction in reboxetine dose should be considered when the two drugs are coadministered (Herman et al., 1999).

4.10 Amprenavir

Amprenavir is a new human immunodeficiency virus (HIV)-1 protease inhibitor. In human microsomes, CYP3A4 is primarily responsible for amprinavir metabolism. Subjects received amprenavir 1200 mg, ketoconazole 400 mg and amprenavir 1200 mg plus ketoconazole 400 mg. Each treatment was separated by 14 days result in increased amprenavir AUC_{0-\infty} by 31% and reduced its C_{max} by 16%. Peak serum concentrations of amprenavir are decreased when given with ketoconazole, and the absorption profile is shifted to the right. Whether this reflects as combined effect on gastrointestinal CYP3A4 and P-glycoprotein inhibition of one excretory rout in preference to the other remains to be determined. Amprenavir increased the AUC_{0-\infty} of ketoconazole by 44 % and increased t_{1/2} and C_{max} by 23% and 19%, respectively. Both agents resulted in substantial inhibition of erythromycin breath test (ERMBT), a specific maker for hepatic CYP3A activity. However the ERMBT did not correlate with clearance of amprenavir, has did the reduction in ERMBT by ketoconazole predict the magnitude of its effect on amprenavir. Suggest that gastrointestinal P-glycoprotein and CYP3A4 contribute substantially to overall clearance of amprenavir. Coadministration of ketoconazole and amprenavir results in a significant increase in AUC for both agents, but the changes are not likely to be clinically important (Polk et al., 1999).
Itraconazole

Itraconazole was first synthesized in 1980. It is a water insoluble, lipophilic triazole analogue. When given orally, it was 5 to 100 times more active than ketoconazole (Heeres, Backx and Van Cutsem, 1984). In addition, unlike ketoconazole, it was active in aspergillosis, meningeal cryptococcosis and sporotrichosis and more desirable pharmacokinetic profile and less toxicity (Warnock, 1989).

1. Chemical and Physical Properties

Chemical structure : $C_{35}H_{38}Cl_2N_8O_4$ (Figure 4)

Synonyms : 4-[4-[4-[4-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolam-4-yl]methoxy]-phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4 triazol-3-one

Molecular weight : 705.6

pKa : 3-4

Solubility : in dimethyl sulfoxide: $>1$ in 100 (w/v)

in alcohol: 1 in 1,000 (w/v)

in water: $<1$ in 1,000,000 (w/v)

Octanol/water partition coefficient : 46,000 (pH8.1)
Figure 3 Chemical Structure of Itraconazole

2. Pharmacokinetics Properties

The pharmacokinetic of itraconazole in humans are characterized by a good oral absorption, extensive tissue distribution, with tissue concentrations many times higher than those in plasma, an elimination half-life of about 1 day, and transformation into a number of metabolites

2.1 Absorption

Following oral administration, itraconazole is rapidly and extensively absorbed with absolute systemic bioavailability of 55%. Itraconazole is only ionized at low pH, such as in the gastric milieu. The plasma concentration time curves of itraconazole in healthy volunteers were a wide interindividual and steady-state pharmacokinetics of 200 mg itraconazole once daily and twice daily in 6 healthy volunteers. The $T_{\text{max}}$ and AUC observed for the once daily dosage was 1.1 mg/l and 15.4 mg/l.hr, respectively and for the twice a day dosage 2.0 mg/l and 39.3 mg/l.hr. Thus, dosage increase between 100,
200 and 400 mg daily produced non-linear increases in the AUC, suggesting that the possibility of saturable metabolic processes (Hardin et al., 1988). Mean peak concentrations of 0.02 mg/l are attained when a 100 mg dose is administered during fasting, while peak concentrations of 0.18 mg/l are attained when the drug is administered after feeding (Wishart, 1987).

2.2 Distribution

As with ketoconazole, itraconazole is highly protein bound (>99%), with only 0.2% available as free drug (Heykants, 1989). Tissue concentrations are 2 to 5 times higher than those in plasma are. Itraconazole penetrates into the cerebrospinal fluid, urine and peritoneum at low concentration, probably reflecting the low concentrations found free in plasma. Penetration into skin and appendages occur at a low rate but accumulates in skin blister fluid and the horny layer for more than 10 days and the distal nail plates for 7 or more months, being delivered via both the nail bed and the matrix. The volume of distribution (10.7 l/kg) of itraconazole is large (Schafer Korting, 1993).

2.3 Elimination

The drug has a prolonged clearance time, with a \( t_{1/2} \) of 15 to 20 hours following a single dose, and 30 to 35 hours following multiple dosing (Hardin et al., 1988).

The main site of metabolism is the liver and involves oxidative degradation of dioxoland, piperazine and triazole ring and oxidative or N-dealkylation of the 1-methylpropyl substituent. More than 30 metabolites were formed. One important metabolite, hydroxyitraconazole, has similar antifungal activity \textit{in vitro} to the parent drug (Mikami et al., 1994). It has a
half-life of about 12 hours and the peak plasma concentration and area under concentration time curve for this metabolite are approximately double those of the parent drug. It is likely that hydroxyitraconazole is formed largely by presystemic metabolism during absorption (Heykants et al., 1989).

The drug is extensively metabolized in the liver and excreted in the urine accounted for 35% of the dose given to tree volunteers and fecal excretion accounted for further 54%. Less than 1% of the active metabolites are excreted in the urine. Metabolism of the drug is not altered by renal dysfunction, hemodialysis or continuous peritoneal dialysis (Boelaert et al., 1988).

Itraconazole appears to be a good substrate of CYP3A in humans and inducers of this isoenzyme such as phenobarbital and rifampin increased the drug metabolism.

3. Mode of Use

The recommended itraconazole dosage for superficial fungal infections is 100 mg once daily at mealtime for: 15 days in patients with tinea corporis/crusris; 30 days, tinea pedis/manuum; 4-8 weeks, tinea capitis and a minimum of 3 to 6 months, onychomycoses. In pityriasis versicolor, vaginal candidiasis and fungal keratitis the recommended dosage is 200 mg once daily for 5 days, 3 days and 3 weeks, respectively. The initial dose in systemic mycoses is 200 mg daily increased to 400 mg daily in 1 or 2 divided doses when oral absorption is questionable and/or response is inadequate. In children the
recommended dose is 3 to 5 mg/kg/day. Itraconazole is contraindicated in pregnancy (Grant and Clissold, 1989).

4. Adverse Effect

Itraconazole is well tolerated at 200 mg daily. Most of the adverse reaction reported are transient, and include gastrointestinal disturbances, dizziness, headache, depressed libido (with normal testosterone levels and leukopenia (Graybill, 1990). The drug has a low incidence of hepatotoxicity, with less than 3% of patients experiencing transient elevations in liver function tests (Cauwenbergh et al., 1987). It has no effect on testicular or adrenal steroidogenesis (Van Cauteren et al., 1987). In a series of 189 patients receiving 50 to 400 mg/day, nausea and vomiting were recorded in 10%, hypertriglyceridemia in 9%, hypokalemia in 6%, increased serum aminotransferase in 5%, rash in 2%, and at least one side effects in 39% (Tucker et al., 1990). Profound hypokalemia has been seen in patients receiving 600 mg or more daily (Sharkey et al., 1991). Doses of 300 mg twice daily have led to other side effects, including adrenal insufficiency, lower limb edema, hypertension and in one patient rhabdomyosis (Sharkey et al., 1991). The evidence of side effects increase with duration of treatment.

4. Drug Interaction

4.1 Lovastatin and Lovastatin acid

Lovastatin is an inactive lactone pro-drug converted in vivo to the corresponding open hydroxy acid, lovastatin acid, which is a competitive inhibitor of HMG-CoA reductase, the rate-limiting step in cholesterol
synthesis. Skeletal muscle toxicity is a rare side effect of HMG-CoA reductase inhibitor. Lovastatin is metabolized in the liver by CYP 3A4. Coadministration of lovastatin with itraconazole, the $C_{\text{max}}$ and the AUC of lovastatin were increased more than 20-fold ($P < 0.001$). The mean $C_{\text{max}}$ of the active metabolite, lovastatin acid, was increased 13-fold (range, 10 to 23-fold) and the $AUC_{(0-24)}$ 20-fold. Itraconazole greatly increase plasma concentrations of lovastatin and lovastatin acid by inhibiting CYP3A4 mediated metabolism probably explains the increased toxicity of lovastatin (Neuvonen and Jalava, 1996).

4.2 Buspirone

Buspirone is a non-benzodiazepine anxiolytic agent that acts as a partial agonist at serotonin receptor of 5HT$_{1A}$ type. The oral bioavailability of buspirone is very low as a result of first-pass metabolism. Pretreatment of itraconazole 200 mg/day for 4 days increased the mean area under the plasma concentration-time curve from time zero to infinity ($AUC_{(0-\infty)}$) of buspirone about 19-fold ($P < 0.05$) compared with placebo. The mean $C_{\text{max}}$ of buspirone was increased about 13-fold ($P < 0.01$) by itraconazole. These interactions were evident in each subject, although a striking interindividual variability in the extent of the elimination half-life of buspirone was not prolonged by itraconazole. The greatly elevated plasma buspirone concentrations resulted in increased ($P < 0.05$) pharmacodynamic effects and in side effects of buspirone. The interaction caused by inhibiting its CYP3A4 mediated first-pass metabolism (Kivisto et al., 1997).
4.3 Felodipine

Felodipine, a dihydropyridine calcium antagonist, is extensively metabolism by CYP3A4. Nine healthy volunteers received 200 mg itraconazole orally once a day for 4 days. On day 4, each ingested a single 5 mg oral dose of felodipine. On average, itraconazole increased the $C_{\text{max}}$ of felodipine nearly 8-fold ($P < 0.001$), the $\text{AUC}_{(0-\infty)}$ about 6-fold ($P < 0.001$) and the elimination half-life 2-fold ($P < 0.05$). The decrease in blood pressure and the increase in heart rate were significantly greater during the itraconazole phase. Itraconazole greatly increases plasma concentrations and effects of felodipine by inhibition of CYP3A4 during the first-pass and elimination phase of felodipine (Jalava et al., 1997).

4.4 Quinidine

Quinidine is eliminated mainly by CYP3A4-mediated metabolism. Itraconazole 200 mg was ingested once a day for 4 days. A single 100 mg oral dose of quinidine sulphate was ingested on day 4. On the average, the peak plasma concentration of quinidine increased to 2.6-fold and the area under the concentration-time curve of quinidine increased to 2.4-fold by itraconazole. The elimination half-life of quinidine was prolonged 1.6-fold and the area under the 3-hydroxyquinidine/quinidine ratio-time curve decreased to one-fifth ($P < 0.001$) by itraconazole. The renal clearance of quinidine decreased 50% by itraconazole, whereas the creatinine clearance was uneffected. The QTc interval correlated with the concentrations of quinidine during both itraconazole and placebo phases ($r^2 = 0.71$ and $r^2 = 0.79$, respectively).
Itraconazole increases plasma concentrations of oral quinidine, probably by inhibiting the CYP3A4 during the first-pass and elimination phase of quinidine. The decreased renal clearance of quinidine might be the result of the inhibition of P-glycoprotein-mediated tubular secretion of quinidine by itraconazole -(Kaukonen et al., 1997).

4.5 Terfenadine

Terfenadine is widely used histamine H₁ receptor antagonist. It is metabolized extensively by CYP3A4 in humans to form 2 metabolites by N-dealkylation and hydroxylation. The case reported after concomitant 60 mg terfenadine orally twice a day with 200 mg itraconazole orally twice a day result in prolonged cardiac QT interval, syncope, and ventricular fibrillation. Serum concentrations of terfenadine were 96 ng/ml on the 2nd day of hospital day and more than 10 ng/ml on day 15th, which normal subjects taking normal doses (60 mg twice a day) of terfenadine, levels of unchanged terfenadine in plasma are usually very low or undetectable (Crane and Shih, 1993).

4.6 Clarithromycin

Clarithromycin is the new macrolide antibiotic, it is appears to be a key drug for prophylaxis and treatment of Mycobacterium avium complex (MAC) infection. Three patients negative for human immunodeficiency virus infection were admitted for pulmonary MAC and aspergillosis infections. They were treated with different drug combinations, but all regimens included clarithromycin for MAC and itraconazole for aspergillosis. All patients experienced an increase in clarithromycin concentrations and clarithromycin: 14-OH-clarithromycin ratio compared with expected range values. They had
no clinical side effects. The time course suggested a possible interaction between clarithromycin and itraconazole, presumably through itraconazole's effects on CYP3A4 activity. A bidirectional interaction can not be ruled out. The data suggest that when necessary, these two drugs can be administered together safely. Further investigation is necessary to determine the extent and clinical consequences of coadministration in humans (Auchair et al., 1999).

4.7 Bupivacaine

Bupivacaine is an amide-type local anaesthetic administered as a racemic mixture of two optically active enantiomers, R-bupivacaine and S-bupivacaine. R-bupivacaine is mainly responsible for the cardiotoxicity of bupivacaine, but it has also greater clearance compared with S-bupivacaine. Pretreatment of 200 mg orally itraconazole, once daily for 4 days, on day 4 racemic bupivacaine 0.3 mg/kg was given intravenous over 60 minutes. 21% and 25% reduces plasma concentrations of R- and S-bupivacaine, respectively, while it had no significant effect on other Pharmacokinetics variables of the enantiomers. Reduction of bupivacaine clearance by itraconazole probably increases the steady-state concentration of bupivacaine enantiomers by 20-25%. This should be taken into account in the concomitant use of bupivacaine and itraconazole, although the interaction seems to be of limited clinical significant (Palkama et al., 1999).
Cytochromes P-450

1. Introduction

Enzymes in the liver and other tissues catalyze xenobiotic biotransformation. Most of the enzymes have been classified as belonging to phase I or phase II pathway of metabolism. Phase I reaction involve hydrolysis, reduction, and oxidation. These reactions expose or introduce a functional group (-OH, -NH₂, -SH or –COOH). These reactions will transform a hydrophobic compound into a form that is more water soluble and can be easily eliminated from the organism through urine or bile. Phase II biotransformation reactions include glucuronidation, sulfation, acetylation, methylation, conjugation with glutathione (mercapturic acid synthesis) and conjugation with amino acids (such as glycine, taurine and glutamic acid).

In phase I pathway, cytochromes P-450 (P450s) are the most active among drug-metabolizing enzymes. These enzymes are also principally responsible for activation of procarcinogens and promutagens. Most clinically used drugs are metabolized to some degrees by P450s.

P450s have been classified based on principally amino acid sequence identity. Families are designated by an Arabic number, with all members of a particular family having more than 40% identity in amino acid sequence. A subfamily consists of enzymes in which the amino acid sequence is more than 55% identical. These are designated by a capital letter. An Arabic numeral is used to represent the individual enzyme. P450s are named CYP followed family, subfamily and individual enzymes, respectively.
The cytochromes P450 are a superfamily of hemoproteins that are the terminal oxidized of the mixed function oxidase system. These found in animals, plants, yeast and bacteria. These enzymes are embedded in the lipid bilayer of smooth endoplasmic reticulum (microsomes).

- The membrane localization is ideally suited for the function of P450s in metabolizing hydrophobic chemicals. These P450s have been referred to as mixed function monooxygenase because they add an atom of oxygen to numerous structurally-diverse substrates. A simplified scheme of oxidative cycle is presented in Figure 5. In the P450s catalytic cycle, the enzyme binds to its substrate (Step 1) and the heme ion is reduced from a valency of +3 to +2 by an electron transferred from NADPH via another flavoprotein called NADPH-P450 oxidoreductase 9 (Step 2). Then O₂ binds to the heme and is reduced by another electron (Step 3). A series of reaction occurs that result in splitting of O₂, production of H₂O and oxidation of the substrate (Step 4). (Correia, 1998).

2. Human Hepatic Cytochrome P450s (CYPs)

Presently, the P450 subfamily consists of 17 CYP gene families in humans (de Wildt et al., 1999). Three main P450 gene family, CYP1, CYP2 and CYP3 are responsible for the vast majority of drugs metabolism and account for at least 70% of the total P450 content in humans liver sample. Although the CYP1 and CYP3 gene families are relatively simple (i.e. CYP1A and CYP3A), the CYP2 gene family is comprised of many subfamilies (e.g., CYP2A, CYP2B, CYP2C, CYP2D, CYP2E, etc).
Figure 4 Cytochromes P-450 cycle in drug oxidations (Correia, 1998: 52)
These isoforms have the same oxidizing center (the heme iron), but different by their protein structures (Lin and Lu, 1998).

For different P450s, the entry of the substrate into the active site and the direct interaction of amino acids in the active site with the substrate govern specificity control.

3. Mechanisms of Induction of Cytochrome P450s

Inducers of cytochrome P450s increase the rate of xenobiotic biotransformation (Batt et al., 1992). Enzyme induction occurs when a drug stimulates the synthesis of more enzyme protein, enhancing the enzyme’s metabolizing capacity. It is somewhat difficult to predict the time course of enzyme induction because several factors, including drug half-lives and enzyme turnover, determine the time course of induction (Cupp and Tracy, 1998; Tanaka, 1998a). One of the intriguing aspects of the CYP is that some of these enzymes, but not all, are inducible. Human CYP1A1, CYP2C9, CYP2E1 and CYP3A4 are known to be inducible. Unlike CYP inhibition, which is an almost immediately response, CYP induction is a slow regulatory process that can reduce drug concentrations in plasma, and may compromise the efficacy of the drug in a time-dependent manner. Unless care is taken in study design, the pharmacokinetic and clinical consequences of CYP induction are often overlooked in clinical studies.

Although the phenomenon of CYP induction has been known for more than 4 decades, only in recent years have begun to uncover the mechanisms involved in induction. From biological point of view, induction is an adaptive
response that protects the cells from toxic xenobiotics by increasing the
detoxification activity. While in most cases CYP induction is the consequence
of an increase in gene transcription, some nontranscriptional mechanisms also
are known to be involved.

In drug therapy, there are 2 major concerns related to CYP induction. First, induction will result in a reduction of pharmacological effects caused by
increased drug metabolism. Secondly, induction may create an undesirable imbalance between toxification and detoxification. Like a double-edged
sword, induction of drug metabolizing enzymes may lead to a decrease in
toxicity through acceleration of detoxification, or to an increase in toxicity
caused by increased formation of reactive metabolites. Depending upon the
delicate balance between detoxification and activation, induction can be a
beneficial or harmful response (Lin and Lu, 1998).

4. Mechanisms of Inhibition of Cytochrome P450s

Enzyme inhibition usually involves competition with another drug for the
enzyme binding site. This process usually begins with the first dose of the
inhibitor, and onset and offset of inhibition correlate with the half-lives of the
drugs involved (Cupp and Tracy, 1998)

The catalytic cycle of P450 consists of at least 7 discrete steps:

(i) binding of the substrate to the ferric form of the enzyme
(ii) reduction of the heme group from the ferric to the ferrous state
    by an electron provided by NADPH via P450 reductase
(iii) binding of molecular oxygen
(iv) transfer of a second electron from P450 reductase and/or cytochrome b5

(v) cleavage of the O-O bond

(vi) substrate oxygenation

(vii) product release.

Although impairment of any one of these steps can lead to inhibition of CYP enzyme activity, step (i), (iii) and (vi) are particularly vulnerable to inhibition.

The mechanism of CYP inhibition can be divided grossly into three categories: reversible inhibitions, quasi-irreversible inhibitions and irreversible inhibitions. Among these, reversible inhibition is probably the most common mechanism responsible for the documented drug interactions (Lin and Lu, 1998; Halpert, 1995).

4.1 Reversible Inhibition

Many of the potent reversible CYP inhibitors are nitrogen-containing drugs, including imidazole, pyridines and quinolines. These compounds can not only bind to the prosthetic heme iron, but also to the lipophilic region of the protein. Inhibitor that simultaneously bind to both regions are inherently more potent inhibitors. The potency of an inhibitor is determined both by its lipophilicity and by the strength of the bond between the lone electron pair on the nitrogen and the prostatic heme iron. For example, both ketoconazole and cimetidine are imidazole-containing compounds that interact with ferric CYP at its sixth axial ligand position. The coordination of a strong ligand to the pentacoordinated iron, or the displacement of a weak ligand from the
hexacoordinated heme by a strong ligand. However, cimetidine is a relatively weak reversible inhibitor of CYP, an apparent result of an intrinsic low binding affinity to microsomal CYP. This latter property is most probably because of the low lipophilicity of cimetidine. On the other hand, ketoconazole, a potent CYP inhibitor, has a high lipophilicity. Similarly, fluconazole contains a triazole that binds to the prosthetic heme iron but is a weak reversible CYP inhibitor, again due mainly to its low lipophilicity.

The quinoline is another class of nitrogen heterocycles that exhibit potent CYP inhibition. Quinidine and its diastereoisomer quinine, both, which are potent reversible inhibitors of debrisoquine 4-hydroxylation, a reaction catalyzed by the CYP2D subfamily.

4.2 Quasi-Irreversible Inhibition via Metabolic Intermediate Complexation

A large number of drugs, including methylene dioxybenzenes, alkylamines, macrolide antibiotics and hydrazines, undergo metabolic activation by CYP enzymes to form inhibitory metabolites. These metabolites can form stable complexes with the prosthetic heme of CYP called metabolic intermediate (MI) complex, so that CYP is sequestered in a functionally inactive state. MI complexation can be reversed, and the catalytic function of ferric CYP can be restored by the highly lipophilic compounds that displace the metabolic intermediate from the active site. Other methods by which the ferrous complex can be disrupted include irradiation at 400 to 500 nm or oxidation to the ferric state by the addition of potassium ferricyanide. Dissociation or displacement of the MI complex results in reactivation of
CYP functional activity. However, in vivo situations, the MI complex is so stable that the CYP involved in the complex is unavailable for drug metabolism, and synthesis of new enzymes is the only means by which activity can be restored. The nature of the MI complexation is, therefore, considered to be quasi-irreversible.

4.3 Irreversible Inactivation of CYP

Drugs containing functional groups can be oxidized by CYP to reactive intermediates that cause irreversible inactivation of the enzyme prior to its release from the active site. Because metabolic activation is required for enzyme inactivation, these drugs are classified as mechanism-based inactivators or suicide substrates. The mechanism-based inactivation of CYP may result from irreversible alteration of heme or protein, or a combination of both. In general, modification of the heme group invariably inactivates the CYP, whereas protein alteration will result in loss of catalytic activity only if essential amino acids, which are vital for substrate binding, electron transfer and oxygen activation, are modified.

4.3.1 Heme Alkylation

Drugs containing terminal double-bound (olefins) or triple-bond (acetylenes) can be oxidized by CYP to radical intermediates that alkylate the prosthetic heme group and inactivate the enzyme. The evidence for heme alkylation includes the demonstration of equimolar loss of enzyme and heme, as well as the isolation and structural characterization of the heme adducts. Heme alkylation is initiated by the addition of activated oxygen to the internal carbon of the double or triple bond and is terminated by binding to heme
pyrrole nitrogen. It is interesting to note that linear acetylenes react with the nitrogen of pyrrole ring A of CYP2B1 in liver microsomes of phenobarbital-induced rat, whereas linear olefins react with the nitrogen of pyrrole ring D.

4.3.2 Covalent Binding to Apoprotein

The best known example of inactivation of CYP through protein modification by a suicide inactivator is that of chloramphenicol. The dichloroacetamido group is an oxidized to an oxamyl moiety that acylates a lysine residue in the CYP active center. This acylation event interferes with the transfer of electrons from CYP reductase to the heme group of the CYP and thereby prevent catalytic turnover of the enzyme. The inactivation by chloramphenicol is not uniform for all CYPs. Studies with rat liver microsomes revealed that CYP2B1, CYP2C6 and CYP2C11 are susceptible to inactivation by chloramphenicol, whereas CYP1A1 and CYP1A2 are resistant.

Although terminal acetylenes have been known to alkylate the prosthetic heme group, some terminal acetylene compounds, such as 2-ethylnynaphthalene, inactivate CYP by binding covalently to the protein with little loss of the heme group. 2-Ethynylnapthalene is converted by CYP2B1 to a ketene, which modifies an active site peptide that includes Thr-302, a highly conserved residue known to play a role in oxygen activation.

Oxidation of sulphur groups in drug molecules can result in the modification of the CYP protein. A variety of sulphur compounds inactivate CYP by binding covalently to protein after the enzyme oxidatively activates them. CYP inactivation by sulphur compounds is believed to be involved with
sulphur oxidation that generates reactive sulphur metabolites. Tienilic acid, a substituted thiophene, is oxidized by yeast-expressed human CYP2C9 to a reactive metabolite, presumably a thiophene sulfoxide that binds covalently to the CYP apoprotein.

The protein modification is caused by formation of a sulphur reactive metabolite, rather than formation of hydrodisulphides (RSSH). Although covalent binding of the protein can be partially prevented by glutathione, the activity of the enzyme inactivated by tienilic acid cannot be restored by glutathione. In addition, diallyl sulphide, a flavour component of garlic, is known to be a potent suicide inhibitor of CYP2E1. The mechanism by which diallyl sulphide inhibits CYP2E1 involves initial oxidation at sulphur to give diallyl sulphone, which then undergoes metabolic activation on 1 or other terminal olefin groups to produce the ultimate reactive species (Lin and Lu, 1998; Halpert, 1995).

5. Clinical Implications

5.1 Induction of Cytochrome P450s

Usually, metabolites are less pharmacologically active than parent drug and, therefore, enzyme induction results in a reduction in pharmacological effect because of increased drug metabolism. In some cases, the metabolites formed during biotransformation may be chemically reactive, so that enzyme induction may result in increased toxicity caused by the increased production of the toxic metabolites. The short half-life of rifampicin results in enzyme induction (CYP3A4, CYP2C), apparent within 24 hours, whereas
phenobarbital, which has a half-life 3-5 days, requires about 1 week for induction (CYP3A4, CYP1A2, CYP2C) to become apparent. These enzyme induction reactions also occur with smoking and long-term alcohol or drugs consumption and can reduce the duration of action of a drug by increasing its metabolic elimination. All these drugs, the clinically most problematic drugs involves the rifampicin series (rifampin, rifapentine and rifabutine) and includes antiepileptic drugs such as phenobarbital, carbamazepine and phenytoin and antituberculous drugs. The CYP1A2 enzyme can be induced by exposure to polycyclic aromatic hydrocarbons, such as are found in char-grilled foods and cigarette smoke. Most human CYP2C and CYP3A subfamily proteins are induced by barbiturates, while human CYP2E1 is inducible by ethanol and isoniazid, although the mechanism involved is complex (Tanaka, 1998a).

5.2 Inhibition of Cytochrome P450s

The clinical incident of drug inhibition will depend on a number of considerations. One of the most important considerations is the therapeutic index of the drug. Patients received anticoagulants, antidepressants or cardiovascular drugs are at a much greater risk than patients receiving other kinds of drugs because of the narrow therapeutic index of these drugs.

For example, ketoconazole and itraconazole are known a potent inhibitor of CYP3A4. In clinical study, ketoconazole and itraconazole increased plasma concentration and effect of midazolam, but ketoconazole is more potent than itraconazole (Olkkola et al., 1994). Coadministration of terfenadine, an antihistamine agent, and ketoconazole led to fatal ventricular
arrhythmias in some patients. Terfenadine is widely used histamine H₁ receptor antagonist. It is metabolized extensively by CYP3A4 in humans to form 2 metabolites by N-dealkylation and hydroxylation. After oral administration of 60 mg dose, terfenadine is usually undetectable in plasma because of extensive first-pass metabolism. Concurrent administration of drugs that inhibit terfenadine metabolism can result in an excessive increase in plasma concentration of terfenadine (Honig et al., 1993; Yun et al., 1993; Woosley et al., 1993).

6. CYP3A Subfamily

Enzymes of the CYP3A subfamily appear to be responsible for the metabolism of the widest range of drugs and endogenous compound in human. CYP3A is the most abundant of the human hepatic cytochromes, accounting for nearly 30% in adult liver and small intestine (Watkins et al., 1987). Activity of CYP3A is variable among individuals, but there are no evidence of genetic polymorphism. Significant amounts of CYP3A are present in the gastrointestinal tract (Von Moltke et al., 1995). CYP3A subfamily consists of at least 3 isoforms: CYP3A4, CYP3A5 and CYP3A7 (de Wildt et al., 1999).

CYP3A4 is the most abundantly expressed CYP and accounts for approximately 25% of the total CYP content in human adult liver and small intestine (Dresser, David Spence and Bailey, 2000 ; Lin and Lu, 1998). CYP3A5 is 85% homologous to CYP3A4. It is expressed at a much lower level than CYP3A4 in the liver, but is predominant isoform in the lung and
stomach and is present in the small bowel and renal tissue (Dresser, David Spence and Bailey, 2000). CYP3A7 is the major CYP isoform detected in human embryonic fetal and newborn liver and does not appear to be present in adult, (Dresser, David Spence and Bailey, 2000 ; de Wildt et al., 1999).

In human liver, CYP3A4 immunoreactivity was detected in midzonal and centrilocubal regions (Ratanasavanh et al., 1991), whereas intestinal CYP3A occurs in the enterocytes lining the lumen of the small intestine (Watkins et al., 1987). Inoue et al. (1992) assigned the CYP3A4 gene to chromosome 7 at band q22.1. The gene is divided in to 13 exons and 12 introns with a length of approximately 27kb (Hashimoto et al., 1993). The therapeutic important drugs of CYP3A4 substrates are such as erythromycin, midazolam, triazolam, cyclosporin, lidocaine and nifedipine (Leeder and Kearns, 1997). The endogenous compounds metabolized by human 3A subfamily including the 6β-hydroxylation of testosterone, cortisol, progesterone and androstanediol; the 2- and 4-hydroxylations of estradiol; and the 16α-hydroxylation of dehydroepiandrosterone 3-sulfate (DHEA-s) (Wrighton and Stevens, 1992). CYP3A4 also metabolizes procarcinogens such as sterigmatocystin and afatoxin B1 (Shimada et al., 1989).

Table 2 is a list of representative substrates, inhibitors and inducers of CYP3A4.
Table 2 List of representative substrates, inhibitors and inducers of CYP3A4
(Venkatakrishnan et al., 2000; Von Moltke et al., 1995)

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Inhibitor</th>
<th>Inducer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunosuppressants</td>
<td><strong>Grapefruit juice</strong></td>
<td>Rifampicin</td>
</tr>
<tr>
<td>cyclosporin</td>
<td>beramottin</td>
<td>Phenobarbital</td>
</tr>
<tr>
<td>tacrolimus</td>
<td>dihydroxyber-gamottin</td>
<td>Carbamazepine</td>
</tr>
<tr>
<td>Hypnosedatives</td>
<td><strong>Diethylstilbestrol</strong></td>
<td>Phenytoin</td>
</tr>
<tr>
<td>midazolam</td>
<td>gestodene</td>
<td>Primidone</td>
</tr>
<tr>
<td>triazolam</td>
<td><strong>H₂ antihistamines</strong></td>
<td>Ritonavir</td>
</tr>
<tr>
<td>alprazolam</td>
<td>cimetidine</td>
<td>Nevirapine</td>
</tr>
<tr>
<td>brotizolam</td>
<td><strong>Tricyclic antidepressants</strong></td>
<td>Dexamethasone</td>
</tr>
<tr>
<td>Calcium antagonists</td>
<td>fluoxetine</td>
<td></td>
</tr>
<tr>
<td>nifedipine</td>
<td><strong>Antiarrhythmic agents</strong></td>
<td></td>
</tr>
<tr>
<td>felodipine</td>
<td>amiodarone</td>
<td></td>
</tr>
<tr>
<td>diltiazem</td>
<td><strong>Calcium antagonists</strong></td>
<td></td>
</tr>
<tr>
<td>Antiarrhythmic agents</td>
<td>diltiazem</td>
<td></td>
</tr>
<tr>
<td>amiodarone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>quinidine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lidocaine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Substrate</td>
<td>Inhibitor</td>
<td>Inducer</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Anti-infectives</td>
<td>Anti-infectives</td>
<td></td>
</tr>
<tr>
<td>erythromycin</td>
<td>troleandomycin</td>
<td></td>
</tr>
<tr>
<td>quinine</td>
<td>erythromycin</td>
<td></td>
</tr>
<tr>
<td>ritonavir</td>
<td>clarithromycin</td>
<td></td>
</tr>
<tr>
<td>saquinavir</td>
<td>clotrimazole</td>
<td></td>
</tr>
<tr>
<td>amprenavir</td>
<td>ketoconazole</td>
<td></td>
</tr>
<tr>
<td>Antineoplastic agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>etoposide</td>
<td>itraconazole</td>
<td></td>
</tr>
<tr>
<td>infosfamide</td>
<td>fluconazole</td>
<td></td>
</tr>
<tr>
<td>vinblastine</td>
<td>indinavir</td>
<td></td>
</tr>
<tr>
<td>Synthetic opioids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fentanyl</td>
<td>amprenavir</td>
<td></td>
</tr>
<tr>
<td>alfentanil</td>
<td>nefinavir</td>
<td></td>
</tr>
<tr>
<td>sufentanil</td>
<td>ritonavir</td>
<td></td>
</tr>
<tr>
<td>The nonsedating antihistamines</td>
<td>Proton pump inhibitor</td>
<td></td>
</tr>
<tr>
<td>terfenadine</td>
<td>omeprazole</td>
<td></td>
</tr>
<tr>
<td>loratadine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>astemizole</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>